|
|
|
| First Name: | C. Anthony | | Last Name: | Altar | | Title: | Founder, NeuroDrug Consulting | | Affiliation: | NeuroDrug Consulting | | Street Address 1: | 11100 Kenilworth Avenue | | Street Address 2: | PO Box 498 | | City: | Garrett Park | | State/Province: | MD | | Zip/Postal Code: | 20896 | Country/Territory: | U.S.A. | | Phone: | (301) 962-0910 | | Fax: | Same, call first | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 4 February 2009]
I am a consultant for Medivation, a company that has a drug in clinical trials for Alzheimer's disease.
|
Stroke and Trauma, Tauopathies, Parkinson Disease, Aging Process, Polyglutamine Disorders (Huntington's, etc.), Alzheimer Disease
|
Drug screening, Neuropathology, Chemistry/Pharmacology, Tau/Cytoskeleton, Signal transduction, Clinical trials, A-beta PP/A-beta, Molecular and Cell biology, Animal Models, Neurobiology, Brain imaging, Neurotransmission, Oxidative Stress
|
Industry, Research institute, Consulting
|
Dr. Tony Altar received his Bachelor and Ph.D. degrees with honors in psychobiology from the University of California at Los Angeles and UC Santa Barbara, respectively. As a post-doctoral scientist and instructor in Parkinson's disease and neuronal plasticity at UC Irvine, Dr. Altar pioneered image analysis of receptor-drug binding in brain. His work created digital subtraction autoradiography to produce quantitative maps of receptors labeled by antipsychotic drugs. While team leader at Ciba-Geigy, he identified the serotonin/dopamine receptor binding profile of atypical antipsychotics, now known as the SDA concept. His research at Genentech and Regeneron Pharmaceuticals supported clinical trials for nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF) in diabetic neuropathy and amyotrophic lateral sclerosis. His team was first to propose roles for BDNF in the etiology and treatment of pain and depression.
As director for global neuroscience at Otsuka America Pharmaceuticals, Inc., Dr. Altar managed the United States and Japan neuroscience teams, and was a member of the antidepressant and antipsychotic clinical development teams. He helped lead the Otsuka-BMS collaboration that produced an FDA approval for the antipsychotic drug, aripiprazole (Abilify) and his laboratory work identified a serotonergic mechanism of Abilify action which led to expanded indications for bipolar disease and depression. As CSO and president of Psychiatric Genomics, Inc., in Gaithersburg, Md., he was responsible for the discovery of genomic alterations in the brains of psychiatric cases. Their research identified insulin- and muscarinic receptor-dependent gene pathways for the treatment of psychosis, and synthesized novel compounds for the treatment of schizophrenia and bipolar disease.
As director of The Biomarkers Consortium in the Foundation for the NIH, Dr. Altar provided support for teams in the cancer, neuroscience, metabolic disorders, and inflammation and immunity disease areas. He promoted consortium relationships with pharmaceutical and biotechnology companies, the NIH, FDA, and patient advocacy organizations, while helping identify over 30 new contributing organizations and 150 participating committee members.
|
Altar CA, O'Neil S, Walter RJ, Jr., Marshall JF (1985) Brain dopamine and serotonin receptor sites revealed by digital subtraction autoradiography. Science 228:597-600.
Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16:517-525.
Altar CA, Marien MR (1989) Preservation of dopamine release in the denervated striatum. Neurosci Lett 96:329-334.
Altar CA, Burton LE, Bennett GL, Dugich-Djordjevic M (1991) Recombinant human nerve growth factor is biologically active and labels novel high-affinity binding sites in rat brain. Proc Natl Acad Sci U S A 88:281-285
Mamounas LA, Blue ME, Siuciak JA, Altar CA (1995) Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929-7939.
Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856-860.
Altar CA (1999) Neurotrophins and depression. Trends Pharmacol Sci 20:59-61.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140.
Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman YV, Young TA, Charles V, Palfreyman MG (2004) Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24:2667-2677.
Altar, C A, Jurata, L W, Charles, V, Lemire, A, Liu, P, Bukhman, Y, Young, T A, Bullard, J, Yokoe, H, Webster, M B, Knable, M B, Brockman, J A (2005) Deficient expression of proteasome, ubiquitin, and mitochondrial genes in hippocampal neurons of multiple schizophrenia cohorts. Biol. Psychiatry 58: 85-96.
Altar, C. A., Hunt, R.A., Jurata, L. W., Webster, M.J., Derby, E., Gallagher, P., Lemire, A., Brockman, J., and Laeng, P. Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol. Psychiatry. (In Press).
125. Altar, C. A., Vawter, M., and Ginsberg, S. D. (2008) Target identification for central nervous system diseases by transcriptional profiling. Neuropsychopharmacology Reviews, Invited review (In press).
|
Mechanism of Alzheimer's disease pathology |
Cai et al. Phospholipase D1 corrects impaired BAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons PNAS 103: 1936, 2006.
Hongpaisan, J. and Alkon, D. L. A structural bais for enhancement of long-term associateiv memory in singel dendritic spines regulated by PKC. PNAS 104: 19571, 2007.
Holmes, C. et al, Long-term effects of AB42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-conrolled phase I trial. The Lancet, 372: 216, 2008 |
Effects of agonist modulators on PKC isoforms on pathways that coordinately regulate amyloid, tau phosphorylation, neurotransmitter function, dendritic process outgrowth, and cognition. |
That convergent agonist modulators that control amyloid, tau phosphorylation, neurotransmitter function, dendritic process outgrowth, and cognition can be exploited to treat Alzheimer's disease. |
Effective drugs that activate those pathways to restore cognition and arrest neurodegeneration in AD. |
Upregulation of these same pathways by their endogenous mediators (BDNF, insulin, IGF-1, glutamate, aspartate, and acetylcholine). |
|
|
Home
